GlobeNewswire Inc.··NaBavarian Nordic Raises 2026 Outlook After $97M U.S. Smallpox Vaccine Contract
Bavarian Nordic raised full-year guidance to DKK 5.5-5.7B revenue with ~28% EBITDA margin after securing $97M U.S. smallpox vaccine production contract.
BVNRYshare buyback programQ1 2026 earnings